Healthy
Conditions
Brief summary
The objective of the study is to compare the bioavailability of a generic product of paracetamol (immediate-release) with that of a reference product when administered to healthy volunteers under fasting condition. The test product is Fortolin Tab 500mg manufactured by Fortune Pharmacal Co. Ltd., and the reference product is Panadol Caplet 500mg manufactured by GlaxoSmithKline (Dungarvan) Ltd. The plasma pharmacokinetic data of paracetamol obtained from two formulations will be used to evaluate the interchangeability of the products.
Interventions
DRUGFortolin Tab 500mg
Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
DRUGPanadol Caplet 500mg
Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
Sponsors
Chinese University of Hong Kong
Fortune Pharmacal Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male and non-pregnant female, 18 to 55 years of age 2. Body Mass Index (BMI) between 18 to 25 kg/m2 3. Accessible vein for blood sampling 4. High probability for compliance and completion of the study 5. Female subjects who are surgically sterile or post-menopausal. Or female subjects of child bearing potential agree to practice abstinence or take effective contraceptive methods (e.g.implanted contraceptives, intra-uterine device or consistent condom plus spermicide use) from the start of screening until two weeks of last dose administration to prevent pregnancy. 6. Have signed the written informed consent to participate in the study.
Exclusion criteria
1. Clinically significant cardiovascular, hepatic, renal, gastrointestinal, neurological, psychiatric, metabolic and other diseases 2. Clinically significant abnormality in physical examination, vital signs, laboratory test results and ECG evaluation 3. Positive results of hepatitis B 4. Moderate smoker (more than 2 cigarettes a day within 3 months prior to the start of first dosing) 5. Moderate consumption of alcohol (more than one drink per day within 3 months prior to the start of first dosing) 6. Have lost or donated more than 350 ml of blood within 3 months prior to the start of first dosing 7. Subjects who are taking prescription or non-prescription medications (except for contraceptives, refer to Inclusion Criteria section) which is likely to be required during the course of the study 8. Use of paracetamol or other analgesic/antipyretic medications within 4 weeks before first dosing 9. Volunteer in any other clinical drug study within 2 months prior to the start of first dosing 10. Hypersensitivity to paracetamol or other drugs in its class 11. History of drug abuse in any form 12. Female subjects who are breastfeeding or pregnant 13. Subjects who are considered not suitable in participating the study due to other factors judged by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak drug concentration (Cmax) of paracetamol | 12 hours |
| Area under the drug plasma concentration-time curve (AUC) of paracetamol | 12 hours |
Secondary
| Measure | Time frame |
|---|---|
| Time to maximum concentration (Tmax) of paracetamol | 12 hours |
| Terminal elimination half-life (t1/2) of paracetamol | 12 hours |
Countries
Hong Kong
Outcome results
None listed